Do you have a FODMAP sensitivity? Are you on a low FODMAP diet? FODMAPS are fermentable oligo-, di-, mono- saccharides and polyols which are forms of carbohydrates found naturally in many foods and cause cause GI distress (1). Learn more about FODMAPS here. Low FODMAP diets are typically the first line of defense & require restriction of foods that contribute to GI distress.
At a recent webinar on Managing Gut Symptoms in Athletes, we learned of a science-backed digestive enzyme blend, FODZYME, which can act as a complement or alternative to a low FODMAP diet (2). Sprinkling FODZYME on trigger foods prior to consumption can help make food painless and support gut health by allowing more fiber-rich, plant-based foods into the diet. Learn more about foods that can be enjoyed with FODZYME here.
We are excited to partner with FODZYME to bring our clients a simple way to help manage occasional bloating, diarrhea, and/or constipation associated with FODMAP intolerance. FODZYME is vegan, gluten- dairy- soy- and casein-free and has no artificial colors or flavors. However, it is not yet 3rd party tested (e.g. NSF Safe in Sport, Informed Sport) so competitive athletes should consider the potential risks before opting to use the supplement. Head to FODZYME to learn more & take their free assessment to see if supplementation may help you. When you are ready to order, use the code NUTRIFY for 15% off your order (Heads up: we earn a small commission when you use our code, but it’s all about giving you access to the best, for less). Questions? Reach out or schedule a complimentary info call to learn more.
References
- Gunnars, K. (2018, November 9). FODMAP 101: A Detailed Beginner’s Guide. Healthline; Healthline Media. https://www.healthline.com/nutrition/fodmaps-101
- Castro Ochoa, K., Samant, S., Liu, A., Duysburgh, C., Marzorati, M., Singh, P., Hachuel, D., Chey, W., & Wallach, T. (2022). In-Vitro Efficacy of Targeted FODMAP Enzymatic Digestion (FODZYME®) in a High-Fidelity Simulated Gastrointestinal Environment. Gastro Hep Advances, 2(3). https://doi.org/10.1016/j.gastha.2022.10.011
